Ginkgo extract EGb 761 demonstrated favourable therapeutic effects in peripheral and central vestibular syndromes. This pragmatic study explored whether administration of EGb 761 in patients with vertigo and dizziness of various aetiologies results in improvement of symptom intensity, posture, gait and ocular motor function, and whether specific patient subgroups benefit most from this treatment.
✦ The floor
Discussion
Signed responses from readers of the wire.
Results from a single open-label (no blinding, no placebo control) pragmatic trial are insufficient to change prescribing or recommendation practice for EGb 761 in vertigo/dizziness management; await higher-quality controlled evidence before adopting.
Vertigo and dizziness are among the most common complaints seen in audiology and ENT practice, and evidence-based pharmacological options remain limited, making any new trial data—however preliminary—worth tracking.
- 01Open-label pragmatic RCT published in Frontiers in Pharmacology (DOI: 10.3389/fphar.2026.1824426).
- 02Intervention was Ginkgo biloba extract EGb 761 across multiple vertigo/dizziness aetiologies.
- 03Included both peripheral (inner-ear) and central (brain-related) vestibular conditions.
- 04Open-label design means patients and clinicians knew the treatment, introducing potential bias.
- 05Pragmatic design improves real-world generalisability but limits causal certainty.
EGb 761 has therapeutic effects on vertigo and dizziness of various aetiologies, including peripheral and central vestibular syndromes.
studypartially supported- PMID
- 42568872
- DOI
- 10.3389/fphar.2026.1824426.
- Journal
- Frontiers in Pharmacology
- Publication type
- clinical_trial
- Evidence level
- 2b
- Population
- Patients with vertigo and dizziness of various aetiologies, including peripheral and central vestibular syndromes
- Intervention
- Ginkgo biloba extract EGb 761 (oral supplementation)
Primary outcomes
Severity of vertigo and dizziness symptoms across multiple aetiologies